Abstract | OBJECTIVE: METHODS: Twelve women and two men were prospectively included in the study. Under short general anaesthesia patients were given injections of 200 U of commercially available BTX-A diluted in 20 ml 0.9% NaCl. Injections were performed submucosally in the trigone and bladder floor under cystoscopic control. Voiding chart, the Visual Analog Scale (VAS) for pain, and urodynamics were performed before treatment and 1 and 3 mo afterward. RESULTS: Overall, 12 patients (85.7%) reported subjective improvement at 1 and 3 mo follow-up. The mean VAS score was significantly reduced at 1 and 3 mo after treatment (p<0.05 for both); at the same time points daytime and nighttime urinary frequency significantly decreased (p<0.01 and p<0.05, respectively), and bladder cystometric capacity significantly increased (p<0.01). Two patients reported incomplete bladder emptying. We did not detect any systemic side effects during or after treatment. CONCLUSIONS: The results of this pilot study indicate that BTX-A intravesical injections are effective in the short-term management of painful bladder syndrome. By modulating afferent C-fiber activity within the bladder walls, BTX-A significantly improves urodynamic parameters and reduces bladder pain and urinary frequency.
|
Authors | Antonella Giannantoni, Elisabetta Costantini, Savino M Di Stasi, Maria Cristina Tascini, Vittorio Bini, Massimo Porena |
Journal | European urology
(Eur Urol)
Vol. 49
Issue 4
Pg. 704-9
(Apr 2006)
ISSN: 0302-2838 [Print] Switzerland |
PMID | 16417964
(Publication Type: Journal Article)
|
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Administration, Intravesical
- Aged
- Botulinum Toxins, Type A
(administration & dosage, therapeutic use)
- Cystitis, Interstitial
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Neuromuscular Agents
(administration & dosage, therapeutic use)
- Pain Measurement
- Pilot Projects
- Prospective Studies
- Statistics, Nonparametric
- Treatment Outcome
|